Radiotherapy After Gross Total Resection of Skull Base Chordoma: A Surveillance, Epidemiology, and End Results Database Analysis of Survival Outcomes
- PMID: 36509323
- DOI: 10.1016/j.wneu.2022.12.012
Radiotherapy After Gross Total Resection of Skull Base Chordoma: A Surveillance, Epidemiology, and End Results Database Analysis of Survival Outcomes
Abstract
Objective: Skull base chordoma is a rare and locally destructive malignancy which presents unique therapeutic challenges. While achieving gross total resection (GTR) confers the greatest survival advantage, the role of adjuvant radiotherapy (RT) for patients who receive GTR remains unclear in the absence of prospective trials. Here, we aim to assess the effect of RT on survival outcomes in skull base chordoma patients who receive GTR by utilizing the Surveillance, Epidemiology, and End Results (SEER) database.
Methods: Patients with diagnostic, primary site, and resection codes specific for chordoma, skull base, and GTR, respectively, were queried in the SEER database (2000-2018). Kaplan-Meier curves (log-rank test) were constructed and Cox proportional hazards models were used to assess survival outcomes.
Results: A total of 115 skull base chordomas undergoing GTR were identified, of which 37 (32%) received no RT and 78 (68%) received RT. Median follow-up was 55.00 months (range: 0.00-227.00). Overall survival (OS) of patients with GTR was 85% and 70% at 5 and 10 years, respectively. Multivariate Cox proportional hazard analysis among chordoma patients undergoing GTR found age ≥65 (P < 0.01) was associated with poorer OS outcomes. RT appeared to trend toward offering benefit in terms of OS in patients after GTR, however this did not achieve statistical significance in the adjusted model (HR = 0.51, CI = 0.23-1.16, P = 0.09). When comparing, disease-specific survival was also not improved in patients undergoing RT (HR = 0.58, CI = 0.23-1.46, P = 0.25).
Conclusions: It remains unclear whether RT after GTR of chordoma improved survival outcomes among SEER database patients.
Keywords: Adjuvant radiotherapy; Disease-specific survival; Gross total resection; Overall survival; SEER; Skull base chordoma.
Copyright © 2022 Elsevier Inc. All rights reserved.
Similar articles
-
Radiotherapy after gross-total resection and subtotal resection of spinal chordoma: a SEER database analysis of overall survival outcomes.J Neurosurg Spine. 2023 Jun 9;39(3):411-418. doi: 10.3171/2023.5.SPINE2396. Print 2023 Sep 1. J Neurosurg Spine. 2023. PMID: 37327146
-
Fractionated radiotherapy after gross-total resection of spinal chordoma: a systematic review of survival outcomes using individualized patient data.J Neurosurg Spine. 2024 Jun 7;41(3):428-435. doi: 10.3171/2024.4.SPINE2491. Print 2024 Sep 1. J Neurosurg Spine. 2024. PMID: 38848586
-
Fractionated Radiotherapy After Gross Total Resection of Clival Chordoma: A Systematic Review of Survival Outcomes.Neurosurgery. 2023 Aug 1;93(2):257-266. doi: 10.1227/neu.0000000000002418. Epub 2023 Feb 24. Neurosurgery. 2023. PMID: 36826997
-
Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database.J Clin Neurosci. 2014 Sep;21(9):1490-6. doi: 10.1016/j.jocn.2014.02.008. Epub 2014 May 19. J Clin Neurosci. 2014. PMID: 24852903
-
Multivariate Analysis and Validation of the Prognostic Factors for Skull Base Chordoma.Front Surg. 2021 Nov 23;8:764329. doi: 10.3389/fsurg.2021.764329. eCollection 2021. Front Surg. 2021. PMID: 34888345 Free PMC article.
Cited by
-
The skull base chordoma patient reported outcome survey (sbCPROS): a patient-centered, disease-specific tool for assessing quality of life in chordoma patients.J Neurooncol. 2025 May;173(1):157-166. doi: 10.1007/s11060-025-04974-6. Epub 2025 Feb 19. J Neurooncol. 2025. PMID: 39971845
-
Chordoma: Genetics and Contemporary Management.Int J Mol Sci. 2024 May 28;25(11):5877. doi: 10.3390/ijms25115877. Int J Mol Sci. 2024. PMID: 38892063 Free PMC article. Review.
-
Exploring perspectives on skull base chordoma management: a modified Delphi approach to consensus.J Neurooncol. 2025 Sep;174(3):609-620. doi: 10.1007/s11060-025-05088-9. Epub 2025 May 22. J Neurooncol. 2025. PMID: 40402197
MeSH terms
LinkOut - more resources
Full Text Sources